MRS

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Nov 5, 2025

Marks Aclarion’s first commercial sales hire with seasoned HealthTech leader and proven track record of advancing musculoskeletal imaging and spinal surgery Experiencing strong commercial traction in UK as first market worldwide with private insurers covering Nociscan Nociscan reimbursed by three of top four private insurers in UK, giving access to more than 5.2 million covered lives Broomfield, CO, November 5, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) -...

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Oct 14, 2025

Debt-free balance sheet with $13.3 million in cash as of today ($15.11 per share fully diluted), providing strategic flexibility for continued commercial growth Nociscan scan volumes increase +89% year-over-year with third consecutive quarter of record utilization across U.S., U.K., and E.U. markets CLARITY pivotal trial progressing on schedule and early 3-month readouts expected Q2 2026 as AI-driven disc pain biomarker validation continues Webcast scheduled for October 20th at 12:00 pm PT at...

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Oct 7, 2025

Company recognized for breakthrough Nociscan solution for chronic low back pain, one of the most widespread health challenges BROOMFIELD, Colo., October 7, 2025 - PRISM MediaWire (Press Release Service - Press Release Distribution) - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today...

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Jul 7, 2025

Meeting adjourned to Monday, July 21, 2025 at 9:30 a.m. Mountain Time Broomfield, CO, July 7, 2025 - PRISM MediaWire - Aclarion, Inc. (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that leverages Magnetic Resonance Spectroscopy ("MRS"), artificial intelligence and a proprietary biomarker to optimize clinical treatments for low back and neck pain, today announced that its Annual Meeting of Stockholders (the “Annual Meeting”) scheduled for July 7, 2025 has...

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Apr 23, 2025

Broomfield, CO, April 23, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM ET. Brent Ness, Chief Executive Officer of Aclarion, will...

Aclarion Announces Reverse Stock Split

Mar 26, 2025

BROOMFIELD, Colo., March 26, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (NASDAQ: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, today announced that effective before market open on Friday March 28, 2025, it will complete a 1-for-27 reverse stock split of its common stock. On September 23, 2024, the Company’s stockholders...

Aclarion Provides Shareholder Update

Mar 13, 2025

Broomfield, CO, March 13, 2025 - PRISM MediaWire - Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today that it has issued an 8k filing that provides an update for stakeholders to review. The filing can be viewed here: The Company intends on filing its 10K by the end of March and...

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Mar 6, 2025

Lenox Hill Radiology (LHR) in New York and New Jersey Imaging Network (NJIN) to add Nociscan across multiple sites Broomfield, CO, March 06, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, announced today plans to expand Nociscan access across key markets in New York...

Aclarion Announces First Commercial Agreement with Scripps Health

Mar 3, 2025

Agreement expands access to Nociscan technology for leading spine physicians and more than 3.2M people in the greater San Diego Metro area Nociscan leverages MR Spectroscopy (MRS) and Augmented Intelligence (AI) to Identify Sources of Chronic Low Back Pain Broomfield, CO, March 3, 2025 - PRISM MediaWire - Aclarion, Inc.,(“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to...

NEWSROOM

Aclarion Appoints Dan Isherwood as UK Commercial Director to Drive Adoption and Market Expansion

Aclarion Provides Corporate Update Highlighting Market Expansion as CLARITY Trial Advances Toward Key Data Catalyst

Aclarion Honored as Finalist for the 2025 Digital Health Hub Foundation: Digital Health Awards at HLTH

Aclarion, Inc. Announces Adjournment of Annual Meeting of Stockholders

Aclarion Releases Updated Investor Presentation in Connection with Appearance at Planet MicroCap Showcase: VEGAS 2025

Aclarion Announces Reverse Stock Split

Aclarion Provides Shareholder Update

Aclarion Announces Expansion Plans with RadNet Affiliates in New York and New Jersey

Aclarion Announces First Commercial Agreement with Scripps Health

Contact Us